Programmaschema Chicago op Schier 2023 – woensdag 7 juni 2023

zie hyperlinks hieronder voor de vervolgdagen

Woensdag 7 juni 2023

08.30 uur Uitchecken

08.45 uur Virtual ASCO – Locatie: Dorpshuis

Miriam Koopman 


Educational: Oligometastatic Renal Cell Carcinoma: Observe, excise, ablate?

K. Runcie When to Play the Systemic Therapy Card 

Oral Abstract Session Genitourinary Cancer—Blaas/nier+ discussants

Choueiri Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study Abs#LBA4500

Grande Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis Abs#4503

Pfister Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial Abs# LBA4507



Gabe Sonke Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up. Abs#5509

Educational: PARP inhibitors: Optimal selection and toxicity management

  1. Tew Updates on the Status on PARP Inhibitors in Ovarian Cancer

Oral Abstract Session Gynaecologic cancer

  1. Harter Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial 

Late breaking abstract session: presentation of Abs# LBA 5507

Moore Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. 

Oral Abstract Session Gynaecologic cancer

  1. Monk KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer Abs#5500
  2. Powell Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) Abs#5503

11.45 uur Afsluiting

12.15 uur Bagage + lunchpakket in Van der Werff

13.15 uur Vertrek pendelbus naar de boot

13.30 uur Vertrek boot naar Lauwersoog (45 min.)

14.15 uur Einde Chicago op Schier

Dinsdag 6 juni 2023
Maandag 5 juni 2023
Zondag 4 juni 2023

© Copyright 2023 - Congress Care - Website door Lemone